Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Investigating HtrA1 as a Possible Indicator of Recurrence in Giant Cell Tumor of Bone

  • By

  • Akif Mirioglu

  • Kaan Ali Dalkir

  • Mehmet Yigit Gokmen

  • Melih Bagir

  • Kivilcim Eren Ates

  • Mehmet Ali Deveci

  • Gülfiliz Gönlüşen

  • Hilmi Serdar Ozbarlas

  • June 12, 2026

Share

  • 1

    Giant cell tumor of bone (GCTB) has a recurrence rate of 15–30% and a metastasis rate of approximately 5%.

  • 2

    HtrA1 expression may serve as a potential indicator for predicting outcomes in patients with GCTB.

  • 3

    The study included 34 patients diagnosed with GCTB, with a minimum follow-up period of 24 months for recurrence assessment.

  • 4

    HtrA1 immunostaining was evaluated using a five-tiered semi-quantitative system to assess expression levels.

  • 5

    Statistical analyses included Fisher’s exact test and Kaplan–Meier analysis to evaluate recurrence and survival.

Original Source(s)

Giant cell tumor of bone: exploring HtrA1 as a potential predictor of recurrence

  • by Akif Mirioglu, Kaan Ali Dalkir, Mehmet Yigit Gokmen, Melih Bagir, Kivilcim Eren Ates, Mehmet Ali Deveci, Gülfiliz Gönlüşen, Hilmi Serdar Ozbarlas

  • June 12, 2026

Related Content

Correction: Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: a systematic review

Correction: Lipid profile-based prognostic nomograms for obstructive colorectal cancer: multi-cohort development and validation

Updated ASTRO Guideline Reflects a New Era for Radiation Therapy in Pancreatic Cancer

An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.

  • by

  • August 14, 2026

  • 6 min